Gabather AB logo

Gabather AB

Gabather AB is developing novel small molecule drugs to treat several diseases originating in the central nervous system (CNS). Key targeted diseases include anxiety, pain, and Alzheimers disease.

Gabather was founded by Prof. Olov Sterner and Mogens Nielsen to commercialise their inventions resulting from more than ten years of collaborative research between Lund University (Sweden) and the Research Institute of Biological Chemistry in Roskilde (Denmark).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.gabather.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Skeppsbron 2, 1 TR,211 20 Sverige
MalmÓ
Sweden
Email
Contact Number

In Mid 2015, Gabather signed a research agreement with UNSW (University of New South Wales, Australia) to study the in-vitro experiments on companys lead substance GT002.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/gabather-ab” connections=”true” suffix=””]

The main assets in Gabather consist of two patent families, Quinazolinderivat and Triazoloderivat, which contain drug candidates in form of small molecules that integrate with the Gaba receptor complex in the brain.

Gabather is publicly traded at Aktietorget with owners such as the scientific inventors behind the molecules, Forskarpatent i Syd AB along with shareholders.